利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.029 秒)

    IGF-1 fusion polypeptides and therapeutic uses thereof
    1.
    发明授权
    IGF-1 fusion polypeptides and therapeutic uses thereof 有权
    IGF-1融合多肽及其治疗用途

    公开(公告)号：US08445434B2

    公开(公告)日：2013-05-21

    申请号：US13416481

    申请日：2012-03-09

    申请人： David J. Glass ,  George D. Yancopoulos ,  Thomas J. Daly ,  Nicholas J. Papadopoulos

    发明人： David J. Glass ,  George D. Yancopoulos ,  Thomas J. Daly ,  Nicholas J. Papadopoulos

    IPC分类号： A61K39/395 ,  A61P3/10

    CPC分类号： C07K14/65 ,  A61K38/30 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/75

    摘要： A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.

    摘要翻译： 包含至少一种IGF1变体组分和融合组分（F）以及任选的信号序列的融合蛋白相对于天然IGF1或IGF2多肽表现出改进的稳定性。 融合组分（F）可以是多聚化组分，例如免疫球蛋白结构域，特别是IgG的Fc结构域或IgG的重链。 IGF1变体显示具有改善的能力，以增加受到恶病质，固定化，老化，慢性疾病，癌症，遗传性疾病，引起萎缩症等引起的肌肉萎缩的受试者的肌肉质量的增加。 IGF1变体在降低患有糖尿病或高血糖症的受试者中的血糖中也是有效的。

    IGF-1 FUSION POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    3.
    发明申请
    IGF-1 FUSION POLYPEPTIDES AND THERAPEUTIC USES THEREOF 有权
    IGF-1融合多肽及其治疗用途

    公开(公告)号：US20120195896A1

    公开(公告)日：2012-08-02

    申请号：US13416481

    申请日：2012-03-09

    申请人： David J. GLASS ,  George D. Yancopoulos ,  Thomas J. Daly ,  Nicholas J. Papadopoulos

    发明人： David J. GLASS ,  George D. Yancopoulos ,  Thomas J. Daly ,  Nicholas J. Papadopoulos

    IPC分类号： A61K39/395 ,  A61P3/10 ,  A61P21/00

    CPC分类号： C07K14/65 ,  A61K38/30 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/75

    摘要： A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.

    摘要翻译： 包含至少一种IGF1变体组分和融合组分（F）以及任选的信号序列的融合蛋白相对于天然IGF1或IGF2多肽表现出改进的稳定性。 融合组分（F）可以是多聚化组分，例如免疫球蛋白结构域，特别是IgG的Fc结构域或IgG的重链。 IGF1变体显示具有改善的能力，以增加受到恶病质，固定化，老化，慢性疾病，癌症，遗传性疾病，引起萎缩症等引起的肌肉萎缩的受试者的肌肉质量的增加。 IGF1变体在降低患有糖尿病或高血糖症的受试者中的血糖中也是有效的。

    IGF-1 fusion polypeptides and therapeutic uses thereof
    4.
    发明授权
    IGF-1 fusion polypeptides and therapeutic uses thereof 有权
    IGF-1融合多肽及其治疗用途

    公开(公告)号：US08158581B2

    公开(公告)日：2012-04-17

    申请号：US12894278

    申请日：2010-09-30

    申请人： David J. Glass ,  George D. Yancopoulos ,  Thomas J. Daly ,  Nicholas J. Papadopoulos

    发明人： David J. Glass ,  George D. Yancopoulos ,  Thomas J. Daly ,  Nicholas J. Papadopoulos

    IPC分类号： A61K38/24 ,  C07K17/00 ,  C07H21/04 ,  C12P21/08

    CPC分类号： C07K14/65 ,  A61K38/30 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/75

    摘要： A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibits improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, such as an immunoglobulin domain, in particular, the Fc domain of IgG or a heavy chain of IgG. IGF1 variants were shown to have improved ability to increase muscle mass in a subject suffering from muscle atrophy caused by cachexia, immobilization, aging, chronic disease, cancer, hereditary condition, an atrophy-causing agent, and the like. IGF1 variants are also effective in decreasing blood glucose in a subject suffering from diabetes or hyperglycemia.

    摘要翻译： 包含至少一种IGF1变体组分和融合组分（F）以及任选的信号序列的融合蛋白相对于天然IGF1或IGF2多肽表现出改进的稳定性。 融合组分（F）可以是多聚化组分，例如免疫球蛋白结构域，特别是IgG的Fc结构域或IgG的重链。 IGF1变体显示具有改善的能力，以增加受到恶病质，固定化，老化，慢性疾病，癌症，遗传性疾病，引起萎缩症等引起的肌肉萎缩的受试者的肌肉质量的增加。 IGF1变体在降低患有糖尿病或高血糖症的受试者中的血糖中也是有效的。